KRAS and serous adenocarcinoma: More specifically, serous cystadenomas do not have mutations in either KRAS or BRAF in contrast to serous borderline tumors and low-grade serous carcinoma, furthermore, mucinous cystadenomas also has a mutation in KRAS [3].